Join the club for FREE to access the whole archive and other member benefits.

UNITY Treats First Patient with UBX0101

25-Jun-2018

Key points from article :

UNITY develops therapeutics to slow, halt or reverse diseases of aging.

Treated first patient in Phase 1 clinical trial evaluating UBX0101.

Patient suffers from moderate to severe osteoarthritis of the knee.

Osteoarthritis is one of the main reasons why it hurts to get old.

Treatment selectively eliminates senescent cells in the joints.

Phase 1 clinical trial of single ascending dose evaluates safety.

The company is going to test a new Senolytic drug in human trials

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Company Representative

Chief Medical Officer at Unity Biotechnology.

Company Representative

Chairman and CEO of UNITY Biotechnology.